Content Spotlight
Podcast: Sustainability equals efficiency, says eXmoor
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
Diminished destocking and stabilized consumable demand are helping bioprocess vendors return to growth, but the slow recovery in funding remains a headwind.
Deal-Making
Pluri has collaborated with Bar-Ilan University to develop placental mucosal associated invariant (MAIT) T-cells for solid tumors. We spoke to the company’s spokesperson to find out more.
Consumer advocacy groups, healthcare unions, and a US senator are all asking for government intervention.
Facilities & Capacity
As clients and employees demand industrywide environmental and social sustainability, companies must learn to integrate it into their daily operations.
The company has tripled manufacturing capacity of antibody drug conjugates (ADCs) at its facility in St. Louis, Missouri.
Global Markets
The 8,000 square-meter facility is the first of the $7.6 billion Bio City project announced by Northway Healthcare Group.
Diminished destocking and stabilized consumable demand are helping bioprocess vendors return to growth, but the slow recovery in funding remains a headwind.
Regulations
“We need to take these concerns about the supply chain seriously and recognize that there’s immense capability in the US already,” says CRO Southern Research.
Consumer advocacy groups, healthcare unions, and a US senator are all asking for government intervention.
Content Spotlight
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
Therapeutic Class
The state will invest $150 million in Long Island’s New York BioGenesis Park (NYBGP).
Drawing a roadmap on cell and gene therapy (CGT) markets, a panel of experts shed light on how investor behaviors and reimbursement practices are changing.
Upstream & Downstream Processing
The company has tripled manufacturing capacity of antibody drug conjugates (ADCs) at its facility in St. Louis, Missouri.
Diminished destocking and stabilized consumable demand are helping bioprocess vendors return to growth, but the slow recovery in funding remains a headwind.